GENB Generate Biomedicines, Inc.
USFinancial ServicesAs of 2026-07-09 12:21
Why GENB matters now
Generate Biomedicines, Inc. (GENB) is a US stock in Financial Services. The latest InvestLog snapshot shows $15.58 with -1.83% on the session and $2.00B in market capitalization; recent performance reads 1-month +16.67% and YTD +14.55%.
The latest financial table shown here is Q1 2026, with revenue of $7.2M, net income of $-61.4M, and EPS of $-0.54. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -11.0%.
The latest indexable market news headline is "AdvanCell Signs 128,000 Square Foot, Full Building Lease at IQHQ's Innovation Park in Andover, Massachusetts" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $23.50. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
-1.18
P/S
58.24
EV/EBITDA
-8.65
DCF Value
$-68.62
FCF Yield
-11.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-737.0%
Net Margin
-637.0%
ROE
38.7%
ROA
-61.5%
ROIC
-89.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.2M | $-61.4M | $-0.54 |
| FY 2025 | $31.9M | $-203.2M | $-4.98 |
| FY 2024 | $20.5M | $-173.8M | $-1.68 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$23.50
Target (Median)
$23.50
Target Range
$22.00 - $25.00
Latest News
Company Info
Sector
Financial Services
Industry
Asset Management
Country
US
Exchange
—
Beta
0.19
Generate Biomedicines, Inc. is a U.S.-based company pioneering generative biology, leveraging machine learning for the discovery and advancement of novel protein therapeutics. Their core approach involves developing drugs using protein-based modalities. The company's pipeline includes several key candidates: GB-0895, an investigational long-acting anti-TSLP monoclonal antibody designed for bi-annual dosing in severe asthma; GB-4362, an MMAE payload neutralizer monoclonal antibody; and GB-5267, a MUC16 CAR-T cell therapy. Integral to their work is the Generate Platform, a sophisticated system engineered to be versatile across diverse therapeutic areas and protein modalities. This platform combines computational innovation with scalable biohardware, allowing them to tackle therapeutic hurdles beyond the capabilities of traditional technologies. Established in 2018, the company was initially known as Generate Biologics, Inc. before rebranding to Generate Biomedicines, Inc. in February 2020. Its headquarters are located in Somerville, Massachusetts.